Reports surrounding Regeneron Pharmaceuticals Inc. shows a mixed bag. While the company's turnaround is gaining momentum, shares were sold by several big players like Thrivent Financial for Lutherans, Voya Investment Management, Corient Private Wealth LLC, and Armistice Capital LLC. On a brighter note, companies like Woodstock Corp, Insight Wealth Strategies, Sicart Associates, and Westwood Holdings Group purchased Regeneron's shares. Various investment firms including Leerink Partners and Goldman Sachs have increased Regeneron's stock price target, pointing towards a positive growth outlook.
Regeneron also announced significant progress in its clinical trials, with success in Lynozyfic Trial, Garetosmab Trial for rare diseases, and positive outcomes for antibodies in Phase 2 and Phase 3 trials. Regulatory successes include positive results from the EMPOWER-Lung 3 trial and FDA approval of Linvoseltamab for Multiple Myeloma. However, there were also points of concern such as an upcoming $83M charge, loss in share price momentum, and recent stock price drop.down.
Regeneron Pharmaceuticals REGN News Analytics from Sun, 22 Jun 2025 07:00:00 GMT to Sat, 20 Dec 2025 14:30:00 GMT - Rating 3 - Innovation 5 - Information 7 - Rumor 6
